key: cord-0924678-obo8mz1x authors: Gao, Yongchao; Liu, Tao; Zhong, Weijun; Liu, Rong; Zhou, Honghao; Huang, Weihua; Zhang, Wei title: Risk of metformin in type 2 diabetes patients with COVID‐19: a preliminary retrospective report date: 2020-09-21 journal: Clin Transl Sci DOI: 10.1111/cts.12897 sha: 1f72d5011838fec7afd68bde1eefe043d2196195 doc_id: 924678 cord_uid: obo8mz1x The current outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection has spread across the world. No specific antiviral agents have been adequately evidenced for the treatment of COVID‐19. Although metformin has been recommended as a host‐directed therapy for COVID‐19, there are some opposite views. And the effect of metformin on the disease severity of COVID‐19 patients with diabetes during hospitalization remains unclear. This study aimed to determine the effect of metformin on disease severity. We enrolled 110 hospitalized COVID‐19 patients with diabetes under either metformin or non‐metformin hypoglycemic treatment for a case‐control study. The primary outcome was the occurrence of life‐threatening complications. There were no differences between the two groups in age, gender, comorbidities, and clinical severity at admission. Blood glucose and lactate dehydrogenase (LDH) levels of the metformin group were higher than those of the non‐metformin group at admission. Other laboratory parameters at admission and treatments after admission were not different between the two groups. Strikingly, the percentage of cases who experienced life‐threatening complications was significantly higher in the metformin group (28.6% (16/56) versus 7.4% (4/54), P = 0.004). Antidiabetic therapy with metformin was associated with a higher risk of disease progression in COVID‐19 patients with diabetes during hospitalization (adjusted odds ratio = 3.964, 95%CI 1.034‐15.194, P = 0.045). This retrospective analysis suggested a potential safety signal for metformin, the use of which was associated with a higher risk of severe COVID‐19. We propose that metformin withdrawal in COVID‐19 patients be considered to prevent disease progression. The current outbreak of coronavirus disease 2019 (COVID-19) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly through human-to-human transmission 1 , and has been declared as "Public Health Emergency Several studies have demonstrated that a higher proportion of ICU admission and more died cases in COVID-19 patients with diabetes than those without diabetes [5] [6] [7] [8] . As a first-line oral hypoglycemic agent for type 2 diabetes patients with satisfying safety profile, metformin has been advised to be repurposed to COVID-19 treatment as a host-directed therapy 9, 10 . However, several researchers recently summarized the current challenges for the prevention and management of COVID-19 patients with diabetes, and indicated the importance of keeping an eye on the potential risk of This article is protected by copyright. All rights reserved metformin 11, 12 . And there is still no clinical evidence that metformin is a friend or foe for diabetes patients with SARS-CoV-2 infection. In this retrospective study, we aimed to identify the effect of metformin on the disease severity of COVID-19 patients with diabetes during hospitalization. Medical record data of confirmed COVID-19 patients were collected in 40 hospitals in Hunan province and 5 hospitals in Hubei province from January 31, 2020 to March 20, 2020. Patient data were extracted from electronic medical records by clinical staff who had been treating patients with COVID-19. A total of 2,399 medical records were retrieved, and all personal information had already been de-identified. We used the followed inclusion criteria to determine the study cohort: (1) COVID-19 patients diagnosed according to the interim guidance of WHO, (2) a history of diabetes, (3) clear information on hypoglycemic medication, and (4) complete documentation on the outcomes. The information regarding patients' age, gender, drug therapy, comorbidities, laboratory parameters, and COVID-19 severities was extracted from medical records. The study was approved by the Institutional Ethics Board of Central South University, China. No consent from the patients was needed. The primary outcomes were defined as the severities of COVID-19, which had been assessed by clinicians and were retrieved directly from the medical records. The This article is protected by copyright. All rights reserved (2) non-metformin: 54 eligible patients received one or multiple antidiabetic drugs other than metformin (median age 71 [IQR 60 -78]; 55.6% female). On admission, as shown in Table 1 , no significant difference was found between the two groups in age (P = 0.375), gender (P = 0.583) and comorbidities (P = 0.821). There was also no difference in initial disease severity between metformin users and nonusers at admission (P = 1.00). Blood glucose and LDH levels on admission were higher in the metformin group (median blood glucose level 8. Table 1 ). However, no difference was found in blood creatinine (P = 0.884), aspartate aminotransferase (AST) (P = 0.088), alanine aminotransferase (ALT) (P = 0.279), D-dimer (P = 0.744), and C-reactive protein (CRP) (P = 0.085) level between the two groups. This article is protected by copyright. All rights reserved No significant difference was found between the two groups in antiviral therapy (P = 0.188), antibiotic therapy (P = 0.605), the use of corticosteroid (P = 0.452), Chinese traditional medicine (P = 0.228) and oxygen support (P = 0.210) after admission. Additionally, no case in the metformin group has metformin withdrawal. Comparison between metformin cases and non-metformin treatment controls revealed a significant difference in disease severity of COVID-19 while hospitalized (X 2 = 12.7, P = 0.004, Table 1 It's apparent that individuals with diabetes increase the risk of SARS-CoV-2 infection and can worsen the outcomes of COVID-19 13 . However, little is known about the effect of metformin, a commonly prescribed medication for type 2 diabetes, on the development of COVID-19 severity. In this retrospective study, we evaluated the impact of metformin on the disease severity of patients with diabetes who are infected with SARS-COV-2. The data showed that among those COVID-19 patients with diabetic complications, compared with patients with non-metformin treatment, This article is protected by copyright. All rights reserved metformin users have a higher proportion of severe disease during hospitalization. Increasing odds of severe disease during hospitalization were associated with the use of metformin. In our study, both blood glucose and LDH levels of patients in the metformin group were higher than those in the non-metformin group at admission. Elevated blood glucose has been reported to correlate with higher levels of proinflammatory This article is protected by copyright. All rights reserved cytokines following viral infection 17 , which contribute to the worsening of COVID-19 18 . In addition, poor glycemic control (> 10.0 mmol/L) was associated with worsening outcomes in patients with diabetes and COVID-19 8 , but it was under well-controlled in both groups of our study. Increased LDH level has also been found associated with a higher risk of mortality and disease progression in COVID-19 patients 19, 20 . There was no difference in the clinical characteristics and other laboratory parameters in metformin and non-metformin cases at admission. These suggest that the conditions of the two groups were comparable. Moreover, our result showed that metformin users were more likely to develop life-threatening complications during hospitalization. Admittedly, the present study had convincing findings and shortcomings. To the current knowledge, our study provided the first clinical evidence for the influence of metformin on COVID-19 patients with diabetes. However, our sample sizes were relatively small, only 110 diabetes patients were involved in our study. Our study also limited as some patients were not discharged, who had been classified according to the most severe assessment during their hospitalization. In conclusion, our preliminary report suggested that the metformin usage may associate with a higher risk of severe COVID-19 in diabetes patients. Due to the widespread use of metformin, formal proof based on clinical trials in different ethnic and geographic populations is needed better to understand the association between metformin and complications of COVID-19. This article is protected by copyright. All rights reserved Diabetes is one of the most important comorbidities of COVID-19 associated with higher mortality. Metformin has been proposed to be a candidate for host-directed treatment for COVID-19. However, recent studies have argued that the risks of metformin in patients with COVID-19 and diabetes need to be considered. We aimed to assess the association between metformin and life-threatening complications by conducting a comparison on COVID-19 patients with diabetes between metformin users and nonusers. Among those COVID-19 patients with diabetes, more severe cases were found in metformin users than in non-metformin cases (28.6% vs. 7.4%, P = 0.004). Antidiabetic therapy with metformin was associated with a higher risk of severe illness (aOR: 3.964, 95%CI 1.034- 15.194 ). This study highlighted a potential safety signal for metformin, the use of which was associated with a higher risk of severe COVID-19. Thus, we propose that metformin withdrawal in COVID-19 patients be considered to prevent disease progression. This article is protected by copyright. All rights reserved Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Accepted Article This article is protected by copyright. All rights reserved 16-covid-19-sitrep-117.pdf? Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes Reducing mortality from 2019-nCoV: host-directed therapies should be an option Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature Practical recommendations for the management of diabetes in patients with COVID-19 Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension A pneumonia outbreak associated with a new coronavirus of probable bat origin The Novel Coronavirus 2019 epidemic and kidneys O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical Characteristics of Coronavirus Disease 2019 in China Lactate dehydrogenase ccepted Article 2,399 Patients who diagnosed as COVID-19 in 45 hospitals up to The authors thank all patients involved in this study and thank Grammarly (www.grammarly.com) for the English language review. This article is protected by copyright. All rights reserved